OBJECTIVES:  To compare how the incidence rates of AML vary across France, Germany, Italy, Spain, UK and Canada. METHODS:  A comprehensive literature review was undertaken to identify incidence data for AML using databases, registries, clinical trials and publications. Detailed bottom up studies were reviewed for sample size, data collection dates, geographic coverage and representation. RESULTS:  The highest rates of AML for target countries were for the UK where incidence was 4.1/100,000, in 2016. This was based on clinical and lab data from Yorkshire and Humber regions, and national health data. A study of patients from south east England between 1999-2000 reported 3.0/100,000. The lowest estimated rates were reported in France with 2.3 and 2.6/100,000 cases for males and females respectively in 2012. However, this data was sourced from registries which only cover ~20% of France. Italian rates were 3.7 and 2.6/100,000 for males and females respectively based on registry data covering 43% of Italy. In Germany, according to 11 population-based cancer registries, there were 13,810 new AML cases (≥15 years) during 2007–2011. AML rates were not retrieved, although crude rates could be calculated based on total population estimates. Coverage in Spain was limited to regional AML studies (north-east Catalonia) where incidence was 3.1/100,000. In Canada, 3.7/100,000 people were diagnosed with AML in 2013 based on registry data with almost complete national coverage. The annual crude incidence rate for Europe was reported as 3.7/100,000 based on the RARECARE project using patients diagnosed between 1995-2002. CONCLUSIONS:  Rates were consistent across the target countries, ranging from 2.3-4.1/ 100,000. Robust data regarding the incidence of treatment naïve and relapsed or refractory patients was not identified, but would be expected to have a lower incidence than the overall AML population.